Thromb Haemost 2005; 94(04): 695-696
DOI: 10.1160/TH05-09-0595
Theme Issue Editorial Focus
Schattauer GmbH

Regenerative Cardiology: There are various ways to prosper

Johannes Waltenberger
1   Department of Cardiology, University Hospital of Maastricht, and Cardiovascular Research Institute of Maastricht (CARIM), Maastricht, The Netherlands
› Author Affiliations
Further Information

Publication History

Received01 September 2005

Accepted after revision01 September 2005

Publication Date:
07 December 2017 (online)

 

 
  • References

  • 1 Menasché P. Stem cells for clinical use in cardiovascular medicine: current limitations and future perspectives. Thromb Haemost 2005; 94: 697-701.
  • 2 Freestone B, Lip GYH, Chong A Y. et al. Circulating endothelial cells in atrial fibrillation with and without acute cardiovascular disease. Thromb Haemost 2005; 94: 702-6.
  • 3 Nadar SK, Lip GYH, Lee K W. et al. Circulating endothelial cells in acute ischeamic stroke. Thromb Haemost 2005; 94: 707-12.
  • 4 Moser M, Patterson C. Bone morphogenetic proteins and vascular differentiation. Thromb Haemost 2005; 94: 713-8.
  • 5 Gissel C, Voolstra C, Doss M X. et al. An optimized embryonic stem cell model for consistent gene expression and developmental studies: a fundamental study. Thromb Haemost 2005; 94: 719-27.
  • 6 Goh G, Self T, Barbadillo Muňoz MD. et al. Molecular and phenotypic analyses of human embryonic stem cell-derived cardiomyocytes: Opportunities and challenges for clinical translation. Thromb Haemost 2005; 94: 728-37.
  • 7 Emanueli C, Lako M, Stojkovic M. et al. In search of the best candidate for regeneration of ischemic tissues: Are embryonic/fetal stem cells more advantageous than adult counterparts?. Thromb Haemost 2005; 94: 738-49.
  • 8 Strauer BE, Brehm M, Zeus T. et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106: 1913-18.
  • 9 Assmus B, Schachinger V, Teupe C. et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCAREAMI). Circulation 2002; 106: 3009-17.
  • 10 Wollert KC, Meyer GP, Lotz J. et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: The BOOST randomised controlled clinical trial. Lancet 2004; 364: 141-8.
  • 11 Hofmann M, Wollert KC, Meyer G P. et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 2005; 111: 2198-202.
  • 12 Janssens S, Dubois C, Dens J. et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: A double-blind, randomized, and placebocontrolled clinical trial. J Am Coll Cardiol 2005; 45: 436A.
  • 13 Senger DR, Galli SJ, Dvorak A M. et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-5.
  • 14 Henry TD, Annex BH, McKendall GR. et al. The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003; 107: 1359-65.
  • 15 Laitinen M, Zachary I, Breier G. et al. VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries. Hum Gene Ther 1997; 8: 1737-44.
  • 16 Murry CE, Wiseman RW, Schwartz S M. et al. Skeletal myoblast transplantation for repair of myocardial necrosis. J Clin Invest 1996; 98: 2512-23.
  • 17 Xia L, McDaniel JM, Yago T. et al. Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. Blood 2004; 104: 3091-96.
  • 18 Gnecchi M, He H, Liang O D. et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005; 11: 367-8.